We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Medicare Panel Supports Provenge as CMS Weighs Coverage Decision
Medicare Panel Supports Provenge as CMS Weighs Coverage Decision
November 19, 2010
Advisors to Medicare have voiced support for Dendreon’s prostate cancer drug Provenge as the Centers for Medicare & Medicaid Services (CMS) decides whether to cover the immunotherapy.